Lighthouse Pharmaceuticals To Present Phase 2 SPRING Trial of LHP588, a Next-Generation Gingipain Inhibitor for the Treatment of P. gingivalis-Positive Alzheimer’s Disease, at CTAD 2025

Written by

in

NOVATO, Calif., Nov. 26, 2025 /PRNewswire/ — Lighthouse Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company pioneering precision medicine to address major unmet…

Continue Reading

More posts

White & Case wins four “Deal of the Year” awards at IJGlobal Investor APAC Awards 2025

November 26, 2025
The Final Countdown on Samsung’s Black Friday Deals – Samsung Newsroom South Africa

November 26, 2025
Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Hospital-Acq

November 26, 2025
New Mars images reveal hidden traces of a recent ice age

November 26, 2025